Loading patent…
AssigneeScynexis, Inc.
InventorsDavid A. Angulo Gonzalez, Stephen Andrew Barat
Estimating the term…
Eufumafungin derivative triterpenoid antifungal compounds are used to treat and/or prevent Pneumocystis pneumonia (PCP) due to their unexpected efficacy against Pneumocystis spp. including their ability to reduce the lung burden of cyst and trophic forms of this fungi. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-β-D-glucan synthesis and are useful in the treatment and/or prevention of PCP since they demonstrate potent activity against Pneumocystis spp. in in vivo models, exhibit adequate tissue penetration into lungs, and are well tolerated.
A method of treating Pneumocystis pneumonia in a subject in need thereof, the method comprising administering to the subject a compound of Formula (II):
A method of treating Pneumocystis jirovecii pneumonia in a human in need thereof, the method comprising administering to the human a compound of Formula (IIa):
A method of treating Pneumocystis jirovecii pneumonia in a human in need thereof, the method comprising administering to the human a pharmaceutically acceptable salt of the compound of Formula (IIa):
Dependencies are inferred from the claim text.